stoxline Quote Chart Rank Option Currency Glossary
  
Puma Biotechnology, Inc. (PBYI)
5.89  -0.33 (-5.31%)    03-01 16:00
Open: 5.35
High: 6.11
Volume: 1,677,122
  
Pre. Close: 6.22
Low: 5.07
Market Cap: 280(M)
Technical analysis
2024-03-01 4:54:29 PM
Short term     
Mid term     
Targets 6-month :  7.6 1-year :  9.02
Resists First :  6.5 Second :  7.73
Pivot price 6.48
Supports First :  4.53 Second :  3.76
MAs MA(5) :  6.32 MA(20) :  6.11
MA(100) :  4.24 MA(250) :  3.58
MACD MACD :  0.3 Signal :  0.4
%K %D K(14,3) :  44.7 D(3) :  52.4
RSI RSI(14): 49.8
52-week High :  7.73 Low :  2.13
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PBYI ] has closed above bottom band by 16.4%. Bollinger Bands are 45% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.12 - 6.16 6.16 - 6.19
Low: 4.99 - 5.02 5.02 - 5.06
Close: 5.82 - 5.88 5.88 - 5.96
Company Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Headline News

Sat, 02 Mar 2024
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript - Yahoo Finance

Fri, 01 Mar 2024
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump - Simply Wall St

Fri, 01 Mar 2024
Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term - Zacks Investment Research

Fri, 01 Mar 2024
Puma Biotechnology Down 15.59% To $5.25 After Earnings Beat - InvestorsObserver

Fri, 01 Mar 2024
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates - Zacks Investment Research

Thu, 29 Feb 2024
Puma Biotechnology Inc reports results for the quarter ended in December - Earnings Summary - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 48 (M)
Shares Float 31 (M)
Held by Insiders 15.3 (%)
Held by Institutions 62.2 (%)
Shares Short 3,210 (K)
Shares Short P.Month 2,900 (K)
Stock Financials
EPS 0.07
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.81
Profit Margin 1.6 %
Operating Margin 15.3 %
Return on Assets (ttm) 8.6 %
Return on Equity (ttm) 12.2 %
Qtrly Rev. Growth -1.8 %
Gross Profit (p.s.) 0
Sales Per Share 4.81
EBITDA (p.s.) 0.79
Qtrly Earnings Growth 0 %
Operating Cash Flow 24 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio 84.14
PEG Ratio 0
Price to Book value 7.27
Price to Sales 1.22
Price to Cash Flow 11.55
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android